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Abstract
Background: Ficus lutea crude acetone leaf extracts were previously shown to stimulate glucose uptake and insulin
secretion of established cells and, inhibit α-amylase and α-glucosidase activities.
Methods: For this study, F. lutea acetone extracts were subjected to solvent-solvent fractionation to yield fractions
with differing polarities (hexane, chloroform, dichloromethane, ethyl acetate, n-butanol and water) in an attempt to
obtain a more potent fraction with in vitro and probably in vivo activity.
Results: Among these fractions, the ethyl acetate fraction had the highest total polyphenol content (100.5 ± 1.6 mg
GAE/g dried extract) and α-glucosidase inhibitory activity (126.8 ± 30.6 μg/ml). It also stimulated the highest glucose
uptake of C2C12 muscle cells and decreased extracellular glucose concentration of H-4-II-E liver cells with low cytotoxic
activity. The ethyl acetate fraction (10.88 ± 0.55 μg/L at 250 μg/ml) enhanced insulin secretion in RIN-m5F pancreatic
β-cells to the same degree as the positive control glibenclamide (11.09 ± 0.07 μg/L at 1μM). While fractionation
increased α-glucosidase inhibition and glucose uptake of cells, in the ethyl acetate fraction, the α-amylase inhibition
and insulin secretion decreased. The weight reducing and glucose control potential of the ethyl acetate fraction in an
obese mouse model, important factors in the amelioration of type II diabetes was determined. The extract had no
statistical significant weight reducing activity.
Conclusion: A major finding was the decrease in the area under the curve of the glucose concentration over time in
animals that were treated with both a change in diet and with the plant extract. This is linked to increased glucose
uptake within the cells, the most likely mechanism is either an increased insulin response or increased insulin secretion.
Keywords: Glucose uptake, Insulin secretion, Digestive enzyme inhibition, Diet induced obesity, Diabetes, Weight
control
Background
Diabetes mellitus is a disease characterised by chronic
hyperglycaemia due to defects in insulin secretion, insu-
lin action or both [1]. Of the different forms of diabetes,
based on pathophysiology, type II diabetes is the pre-
dominant form of the disease accounting for 90 % of all
cases globally in both developed and developing coun-
tries. The pathogenesis of type II diabetes is complex
and involves an interaction between genetic susceptibil-
ity and environmental factors, especially the consump-
tion of diets that promote obesity coupled with physical
inactivity. With an increase in sedentary lifestyles glo-
bally, type II diabetes mellitus is considered one of the
most rapidly growing non-communicable diseases and is
currently the fourth to fifth leading cause of death [2].
The World Health Organisation (WHO) has estimated
that 171 million people were diagnosed with diabetes
mellitus in 2000 and predicts an increased prevalence of
366 million cases by 2030 if no action is taken [3].
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While many therapies such as lifestyle intervention
with moderate exercise and weight loss with pharmaco-
logic agents can control many aspects of type II diabetes,
none has so far convincingly demonstrated an ability to
decrease the progressive loss of pancreatic insulin
secretory function that eventually requires exogenous in-
sulin supplementation [4, 5], or the development of
other pathological complications. Other concerns asso-
ciated with the use of conventional treatments are
their inherent side effects such as abdominal discom-
fort, anorexia, diarrhoea, hepatic and renal impairment
[4, 5]. As a result, newer and more effective drugs need
to be developed. One proposed method to find a safe
and effective therapeutic agent would be to use a me-
dicinal plant which has a history of being safe, effect-
ive, low cost and having a lower incidence of adverse
effects, although the latter may just be an unproven
perception [6].
Numerous phytochemicals have been recognised for
their potential health benefits. Recent studies have indi-
cated that the consumption of polyphenol-rich remedies
are associated with reduced risks for a variety of non-
communicable diseases including diabetes [7]. In a pre-
vious study, we could show that a Ficus lutea acetone
extract contains polyphenol compounds that influenced
the inhibition of α-amylase and α-glucosidase activities
[8], as well as glucose uptake of cells and insulin secre-
tion [9]. For this study we evaluated F. lutea acetone ex-
tracts by fractionation to determine if potentizing is




The leaves of F. lutea Vahl, an attractive tree with wide
glossy leaves were collected at the Manie van der Schijff
Botanical Garden (University of Pretoria), South Africa
in February 2009, and a voucher specimen (PRU
074568) was conserved in the HGWJ Schweikerdt Herb-
arium of the University of Pretoria. The dried ground
leaves of F. lutea (5 g) were extracted and dried as previ-
ously reported [9, 10]. Thereafter, the weighed dried
crude acetone extract was re-dissolved in 50 % acetone
in water, and successively and exhaustively partitioned
(by liquid-liquid extraction) with hexane, chloroform,
dichloromethane, ethyl acetate, n-butanol and water (in
order of increasing polarity). Each fraction was extracted
thrice and concentrated using a rotary evaporator (Büchi
R-114). The partially dried fractions were dispensed into
pre-weighed glass vials and allowed to dry at room
temperature under a stream of cold air. The dried frac-
tions were stored at 4 °C until they are used. The ethyl
acetate fraction was prepared every two weeks for ani-
mal experiments to reduce oxidation.
In vitro assays
Total polyphenol content The total polyphenol content
was determined as previously described [8]. Briefly, to
100 μl of fraction (1 mg/ml in 80 % methanol) was
added 500 μl Folin-Ciocalteu reagent (1/10 dilution) and
1000 μl of distilled water. The mixture was allowed to
stand for 1 min at room temperature, where after 1500
μl of 20 % Na2CO3 solution was added. The final mix-
ture was shaken and incubated for 1 h in the dark at
room temperature. The absorbance was measured at 760
nm using a plate reader (Versamax Molecular Devices).
Gallic acid was used as standard. All assays were done in
triplicate on one day and repeated on three different oc-
casions. The results are expressed as mg of gallic acid
equivalent (GAE) per gram dry weight of crude extract.
α-Amylase inhibition assay The α-amylase inhibition
assay made use of the method described by Ali et al.
[11] as earlier reported [8]. To 40 μl of each fraction
(10 mg/ml in DMSO) were added 200 μl of ice cold
porcine pancreatic α-amylase (type VI) at 4 U/ml and
160 μl of distilled water in a screw-up plastic tube. The
content was gently mixed and incubated at 25 °C for 5
min. This was followed by the addition of 400 μl of po-
tato starch (0.5 % w/v) in 20 mM phosphate buffer (pH
6.9), and incubation for 3 min. An aliquot of the mix-
ture (200 μl) was dispensed into a separate tube con-
taining 100 μl of DNS colour reagent solution (96 mM
3, 5-dinitrosalicylic acid, 5.31 M sodium potassium tar-
trate in 2 M NaOH) and was placed into an 85 °C water
bath. After 15 min, the tube was removed from the
water bath, cooled and the content was diluted with
900 μl distilled water. α-Amylase activity was deter-
mined by measuring the absorbance of the mixture at
540 nm. Acarbose was used as positive control, for
solvent control (100 % enzyme activity), fraction was
replaced by DMSO while for the blank enzyme solution
was replaced with distilled water and the same proced-
ure was carried out as above. The assays were run in
triplicate and repeated thrice. The α-amylase inhibition
activity was expressed as:






ΔAControl ¼ ATest ‐ ABlank
ΔASample ¼ ATest ‐ ABlank
α- Glucosidase inhibition assay The α-glucosidase in-
hibition assay was done by using the method of Bhandari
et al. [12] as earlier described [8]. Sucrose (200 μl of a 56
mM solution) dissolved in 0.1 M phosphate buffer (pH 7)
was mixed with 100 μl of fraction (2.5 mg/ml in 50 %
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DMSO) in a test tube. After pre-incubation at 37 °C for 5
min, 200 μl of rat intestinal α-glucosidase solution was
added. Acarbose was used as positive control while solvent
(50 % DMSO) replaced the fraction to represent 100 % en-
zyme activity. After thoroughly mixing, the samples were
incubated for 20 min and then the reaction was stopped
by adding 750 μl of 2 M Tris-HCl buffer (pH 6.9). The
amount of liberated glucose was determined by glucose
oxidase method and absorbance was measured at 540 nm.
All assays were done in triplicate and repeated thrice. The
α-glucosidase inhibitory activity was calculated as done for
α-amylase activity above.
Calculation of EC50 The concentration of fractions of
F. lutea that inhibited 50 % of the activity of α- amylase
and α-glucosidase termed half maximal effective concen-
tration (EC50) was determined by the Kinetica 5
(Thermo) programme as earlier reported [8].
Glucose uptake The level of glucose uptake was deter-
mined using the methods of Yin et al. [13] and
Deutschlander et al. [14] as earlier described [9].
C2C12 muscle myocytes (25 000 cells/ml) and H-4-
11-E hepatoma cells (30 000 cells/ml) suspended in
DMEM supplemented with 0.25 % BSA were seeded
(200 μl) into wells of 96-well plates. After incubation
at 37°C in a 5 % CO2 incubator for 4 days (C2C12)
and 2 days (H-4-11-E), the cells in the plates were
used for the glucose uptake assay. Prior to the glucose
uptake assay, the fractions were dissolved in DMSO to
a concentration of 100 mg/ml which was further di-
luted (15 μl – 250 μl) with appropriate growth
medium before use in the assay. The cells were incu-
bated for 1 h (C2C12) and 3 h (H-4-11-E) with the
various treatments. Insulin (Lantus) (1, 10 μU) served
as the positive control. After the incubation period,
the glucose concentration in the medium was deter-
mined by the glucose oxidase method with absorbance
measured at 540 nm. The assays were run in triplicate
and repeated thrice. The percentage glucose uptake
was calculated as the percentage change in absorbance
in comparison to the untreated cells using the follow-
ing formula:






ΔAControl ¼ Absorbance Untreated cellsð Þ
ΔASample ¼ Absorbance Treated cellsð Þ
The toxicity of the fractions to the C2C12 muscle and
H-4-II-E liver cells was concurrently determined after
the exposure using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay [15]. In
short, after the removal of the supernatant from cells
for glucose assay, the cells were rinsed once with phos-
phate buffered saline (PBS) (200 μl). Then fresh
medium (200 μl) containing 30 μl of MTT (5 mg/ml in
PBS) was added to each well and further incubated for
4h. Subsequently, the medium was carefully aspirated
without disturbing the formazan crystals and replaced
with 50 μl of DMSO. The absorbance of the coloured
formazan was measured at 570 nm after gentle shaking
using a plate reader (VERSAmax). The percentage cell
viability was calculated as the absorbance of the treated
well divided by the absorbance of the solvent control
well. The LC50 (concentration that was lethal to 50 %
of the cells) were calculated from a plot of the log of
concentration versus cell viability.
Insulin secretion assays The amount of insulin secreted
by RIN-m5F cells was determined by the method of Per-
saud et al. [16]. The RIN-m5F cells (100 000 cells/ml)
were suspended in fresh growth medium (RPMI-1640
supplemented with 10 % FBS, 10 mM HEPES and 1 mM
sodium pyruvate) and seeded (200 μl) into 96-well
plates. Cells were incubated at 37 °C in a 5 % CO2 incu-
bator to allow for adherence for 48 h. Thereafter, the
medium was removed and cells were incubated in a
glucose-free Krebs-Ringer buffer pH 7.4 supplemented
with 1 mg/ml BSA and 10 mM HEPES for 2 h. The
medium was removed and replaced with 100 μl of
glucose-free Krebs-Ringer buffer containing ethyl acetate
fraction at 4 concentrations (62.5, 125, 250 and 500 μg/ml).
Glibenclamide (1, 10, 100 μM) was used as positive control.
The cells were incubated for 1 h. The insulin content
of supernatants was determined using rat insulin ELISA
kit (DRG). The assays were run in duplicate and re-
peated three times. Insulin content was calculated from
a calibration curve of the absorbance values for calibra-
tors against insulin concentration using the linear
equation based on the curve. The amount of insulin
secreted was expressed as μg/L.
In vivo assay Healthy 5 weeks old male CD1 mice
(n = 40) were housed singly (to limit fighting) at the
University of Pretoria Biomedical Research Centre
(UPBRC) in conventional Eurostandard type II cages
(Techniplast) on cloth bedding at the temperature of 22 °C
(±2 °C), under controlled relative humidity (50 % – 60 %)
in a light/dark cycle of 12 hours. Environmental enrich-
ments were provided to keep the mice busy. The mice had
free access to water and standard rodent chow for one week
during the acclimatisation period. The animal experiment
was approved by the Animal Use and Care Committee of
the University of Pretoria with approval number 0V60 and
in compliance with the South African National Standard on
the housing and care of laboratory animals.
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After acclimatisation, all mice were fed a purpose-
made high caloric diet of standard rodent diet contain-
ing 42 % (w/w) fat and 36 % (w/w) sugar for about 12
weeks to induce obesity. Once obesity was attained (ani-
mals being 5 g heavier than the normal mass for the spe-
cies at the specific age), mice were randomly assigned
into one of the four treatment groups (n = 10) and kept
on the diet of a particular treatment plan for the next 7
weeks. The study was undertaken as two independent
experiments as follows; Treatment Plan 1: High caloric
diet (HCD) intake including the ethyl acetate fraction at
1 mg/kg (w/w) to determine if weight loss was possible
in the presence of a high-caloric diet. Treatment Plan 2:
Normal diet (ND) intake including ethyl acetate fraction
at 1 mg/kg (w/w), to determine if weight loss was pos-
sible in obese animals switched to a normal caloric diet.
Diets were prepared fresh every two days and animal
feed was changed at regular intervals (every Monday,
Wednesday and Friday) to limit oxidative change of the
feed. Both treatments were compared to equivalent
caloric non-medicated food
Ante-mortem parameters monitored included deter-
mining body mass, food intake and faecal mass for each
mouse. For the latter the faecal material was carefully re-
moved from the cloth bedding and weighed. The differ-
ence between feed intake and faecal weights before
treatment and after the treatment period was used to es-
timate that specific point’s degree of nutrient absorption.
Blood glucose was monitored using the glucose toler-
ance test (GTT). Following a 6 hour fast period, mice
were treated with 2 g of glucose/kg body weight (SABAX
50 % dextrose) intraperitoneally (i.p). Blood glucose
levels were measured using the Contour TS glucose test
strips (Bayer) and glucometer at 5, 10, 15, 30, 60 and 90
minutes. The entire process was repeated after 6 weeks
of treatment. The values of area under the glucose-time
curve (AUC) were calculated with SPSS 20 (IBM). Post-
mortem parameters monitored included serum chemis-
try parameters for alkaline phosphatase activity (ALP),
alanine aminotransferase (ALT), urea, creatinine, total
protein, cholesterol, globulin, albumin and triglycerides
using an automatic analyser and full necropsies.
Statistical analyses Statistical analyses were evaluated
by one-way analysis of variance (ANOVA) and consid-
ered to be significantly different at p 0.05. Non-normal
data were log-transformed prior to statistical testing.
When significance was found, location of significance
was determined by Bonferroni and Tukey HSD multiple
comparison post hoc tests. All analyses were undertaken
in SPSS 20 (IBM). Data are presented as the mean ±
standard error of mean (S.E.M.). For the glucose toler-
ance test differences before and after treatment were
ascertained using a paired t-test. For the degree of ab-
sorption, differences before and after treatment were de-
termined using a paired t-test, following natural




The total polyphenol content of the six fractions var-
ied widely (Table 1), from 10.32 ± 0.82 to 100.51 ± 1.60
mg GAE/g dry weight of extract. The polyphenol con-
tent of the intermediate polarity ethyl acetate fraction
was the highest (100.51 ± 1.60 mg/g dry weight of ex-
tract) and was significantly higher than the other frac-
tions of lower or higher polarity (p˂0.001). This was
followed by the n-butanol fraction (79.58 ± 0.50 mg/g
dry weight of extract).
The concentration of fractions that inhibited 50 % of α-
amylase and α-glucosidase activities (EC50) is presented in
Table 1. The n-butanol fraction was the most potent inhibi-
tor of the α-amylase enzyme (EC50 = 26.50 ± 1.22 μg/ml)
followed by the ethyl acetate fraction (39.53 ± 7.10 μg/ml)
with a significant difference between the two (p˂0.05). Con-
versely the ethyl acetate fraction was the most potent in-
hibitor of the α-glucosidase enzyme (EC50 = 126.78 ± 30.62
μg/ml) followed by the n-butanol fraction (195.17 ± 63.60
μg/ml) with a significant difference between the two
Table 1 The total polyphenol content and EC50 of α-amylase and α-glucosidase activity of fractions of F. lutea extract
Fractions aTotal polyphenol (mg GAE/g dry weight extract) aα-Amylase inhibition (EC50) μg/ml aα-Glucosidase inhibition (EC50) μg/ml
Hexane 14.86 ± 1.43b ˃1000 ˃1000
Chloroform 10.32 ± 0.82b ˃1000 ˃1000
Dichloromethane 11.83 ± 2.32b ˃1000 854.51 ± 56.92c
Ethyl acetate 100.51 ± 1.60c 39.53 ± 7.10c 126.78 ± 30.62e
n-Butanol 79.58 ± 0.50d 26.50 ± 1.22d 195.17 ± 63.60d
Water 13.34 ± 0.85b ˃1000 558.40 ± 51.67c
fAcarbose - 7.71 ± 0.42b 6.28 ± 0.03b
aValues are means of triplicate determinations done three times (n = 9) ± standard error;
b,c,d,eNo significant difference between extracts with same value, but significant difference p ˂ 0.05 between different values
fPositive control for α-amylase and α-glucosidase
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(p˂0.05). The EC50 values for the non-polar extracts in
both assays were higher than the highest concentration
tested. The EC50 for acarbose against activities of α-amylase
and α-glucosidase were much lower at 7.71 ± 0.42 μg/ml
and 6.28 ± 0.03 μg/ml respectively.
The effect of the fractions (15 μg/ml – 500 μg/ml) on
glucose uptake in C2C12 muscle cells is presented in Fig. 1a.
Of all the fractions, only the ethyl acetate and n-butanol
fractions significantly (p˂0.001) increased glucose uptake in
the cells in a dose related manner with the ethyl acetate
fraction inducing the highest glucose uptake of 31.2 ± 1.5 %
at 500 μg/ml followed by the n-butanol fraction at 25.9 ±
1.2 % as the same concentration. The maximum uptake
stimulated by the ethyl acetate and n-butanol fractions
at 500 μg/ml was significantly (p 0.05) higher than
the 19.1 ± 3.7 % stimulated by insulin (positive control)
at 10 μU. The effect of fractions (15 μg/ml – 500 μg/ml)
on extracellular glucose concentration of H-4-11-E liver
cells is presented in Fig. 1b. Only the ethyl acetate and
n-butanol fractions significantly (p˂0.001) decreased
extracellular glucose concentration in a dose related
manner with the ethyl acetate fraction leading to the
greatest decrease (40.0 ± 2.8 %) at 500 μg/ml, followed
by the n-butanol fraction (25.9 ± 1.4 %) at the same
concentration.
The cytotoxic effect of the fractions against C2C12
muscle and H-4-II-E cells is presented in Table 2.
Among all the fractions, the hexane fraction is the least
cytotoxic to C2C12 muscle cells (the LD50 is greater than
1000 μg/ml) while the chloroform (564.2 ± 15.7 μg/ml)
and ethyl acetate (562.9 ± 4.9 μg/ml) fractions are the
least cytotoxic to the H-4-II-E liver cells. However, the
n-butanol fraction is the most cytotoxic fraction to
both cells; the C2C12 muscle (53.3 ± 6.2 μg/ml) and H-
4-II-E liver (148.9 ± 2.5 μg/ml) cells.
With the ethyl acetate fraction being the most active
fraction in stimulating glucose uptake in the treated
C2C12 muscle and H-4-II-E cells and relatively low
cytotoxicity, only this fraction (62.5 μg/ml – 500 μg/ml)
was further investigated for its insulin secretion activity.
The RIN-m5F pancreatic cells exposed to ethyl acetate
produced a dose related increase in insulin secretion
(Fig. 2). The insulin release increased significantly
(p˂0.001) from 6.58 ± 0.24 μg/L (at fraction concentra-
tion of 62.5 μg/ml) to 10.88 ± 0.55 μg/L (at fraction con-
centration of 250 μg/ml). The 500 μg/ml dose had no
superior response to the 250 μg/ml dose, indicating that
the maximum effect has plateaued. Similarly the RIN-
m5F pancreatic β-cells exposed to glibenclamide (posi-
tive control) significantly (p˂0.001) increased insulin se-
cretion in a dose dependent manner with the highest
insulin secretion (12.44 ± 0.07 μg/L) at the concentration
of 100 μM.
In vivo assays
The initial mean weight of the CD1 mice at period 0
(Fig. 3a) before commencement of treatment was
40.45 ± 2.35 g (HCD), 41.02 ± 1.12 g (HCD with treat-
ment), 44.77 ± 0.48 g (ND) and 42.39 ± 1.88 g (ND
with treatment). The mice were hereafter fed their re-














































Fractions of Ficus lutea crude acetone extract
b
Fig. 1 Glucose concentration (a) C2C12 muscle cells glucose uptake
and (b) H-4-11-E liver cells extracellular glucose (expressed as percentage
of untreated control cells ± standard error of mean, n= 9) exposed to
the fractions of F. lutea extract and insulin as positive control
(100 μU = 3.64 μg/ml). Fractions: 500, 250, 125, 63,
31, 15 μg/ml; Insulin: 10, 1μU
Table 2 Cytotoxicity activity of fractions of F. lutea extract




Hexane >1000 406.9 ± 5.4
chloroform 236 ± 11.7 564.2 ± 15.7
Dichloromethane 478.6 ± 12.8 389.4 ± 15.6
Ethyl acetate 508.0 ± 10.3 562.9 ± 4.9
n-Butanol 53.3 ± 6.2 148.9 ± 2.5
Water NT NT
Values are means of triplicate determinations done three times
(n = 9) ± standard error
ND: Not tested
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measured three times a week when food was changed.
The body weight of the control mice fed the HCD and
the ND gradually increased throughout the study
more than that of their comparative treatment groups,
with the HCD having the greater increase. Conversely,
the body weight of mice on treatment in conjunction
with a HCD and ND with the ethyl acetate fraction
showed a gradual decrease in body weight throughout
the study, with the mice on ND and treatment having
the greatest reduction. None of these differences was
significant (p = 0.18) between the treatments and their
controls. The final mean weight of mice at the end of
the treatment plan was 44.14 ± 4.67 g (HCD group),
40.88 ± 0.92 g (HCD with treatment group), 45.90 ±
2.10 g (ND group) and 39.54 ± 1.34 (ND with treatment
group). A comparison of the period 0 weight (initial
mean weight) to the period 21 weight (final mean
weight) of mice (Fig. 3b) showed that HCD mice had a
significant (p = 0.04) increase in body weight (13.39 %),
























Ethyl acetate fraction Glibenclamide    
Fig. 2 Insulin secretion of RIN-m5F pancreatic cells (expressed as
percentage of untreated control cells ± standard error of mean,
n = 6) exposed to the ethyl acetate fraction and glibenclamide as
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Fig. 3 The effect of diets on body weight of CD1 mice. a The initial body weight at period 0 was when obese state was attained by mice prior
to commencement of treatment for about 7 weeks during which body weight was measured thrice weekly until period 21 of final weight and (b)
Body weight of mice before and after treatment on high caloric and normal diet with and with treatment (ethyl acetate fraction) (mean ± SEM)
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treatment (3.43 % and 3.23 % respectively). No change
was seen in the animals switched to the ND.
After induction of obesity the mean food intake
(period 0) before commencement of treatment varied
(9.50 ± 1.42 g, HCD group; 9.40 ± 1.01 g, HCD with
treatment group; 10.50 ± 1.12 g, ND group and 10.60 ±
1.20 g, ND with treatment group) but did not differ sig-
nificantly. The mice were fed their respective diets for
about 7 weeks while food intake was measured three
times a week when food was changed (Fig. 4a). In gen-
eral the mice placed on ND ate more food than those on
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Fig. 4 The effect of diets on food intake and feacal weight of CD1 mice. a Food intake and b Faecal weight at period 0 was when obese state
was attained by mice prior to commencement of treatment for about 7 weeks during which food intake and faecal weight were measured thrice
weekly until period 21 for final food intake, and (c) Nutrient absorption (mean ± S.E.M.) before and after the treatment period. The nutrient
absorption was estimated as the difference between actual food intake and faecal weight
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food uptake significant. The final mean food intake at
the end of the study (period 21) was 10.60 ± 1.07 g
(HCD group), 9.00 ± 0.98 g (HCD with treatment group),
14.00 ± 0.53 g (ND group) and 12.20 ± 0.98 g (ND with
treatment group). The initial mean faecal weight
(period 0) prior to commencement of treatment varied
from 2.00 ± 0.36 g (HCD group), 2.10 ± 0.28 g (high cal-
oric with treatment group), 1.80 ± 0.20 g (ND group) to
2.30 ± 0.26 g (ND with treatment group). Mice fed on a
ND had significantly higher mean faecal weights
(p˂0.01) than those on HCD irrespective of treatment
(Fig. 4b). At the end of the study the final mean faecal
weight (period 21) for the mice were 2.80 ± 1.14 g
(HCD group), 1.67 ± 0.33 g (HCD with treatment
group), 6.25 ± 0.30 g (ND group) and 4.60 ± 0.28 (ND
with treatment group). The estimated nutrient absorp-
tion per group was compared before and after treat-
ment (Fig. 4c). No differences in nutrient absorption
were present for the animals on the HCD. For the ani-
mals switched to the ND, a significant decrease in nu-
trient absorption was evident for both groups. For the
diet change alone this was 19.3 % (p = 0.04) and for the
diet change with treatment this was 25.8 % (p = 0.0097).
No difference was present between the two groups
switched to the normal caloric diet.
The average fasting blood glucose concentration was
8.43 ± 1.16; 8.83 ± 0.57; 8.90 ± 0.88 and 8.82 ± 0.58 mM
for obese mice prior to commencement of treatment
placed in HCD; HCD with treatment; ND; and ND with
treatment groups respectively. These values did not dif-
fer significantly (p˂0.05) (Fig. 5a). After 6 weeks of treat-
ment the average fasting blood glucose concentrations
for the CD1 mice did not differ significantly between the
treatment groups (Fig. 5b). There was also no significant
difference in the blood glucose concentration for the
mice in the treatment groups after the administration of
the glucose bolus. The pre-treatment and post-treatment
area under the curve (AUC) of glucose concentration
versus time profiles were compared (Fig. 5c), the mice in
the high-caloric group showed an increase in total
plasma glucose concentrations (9.97 %); the high caloric
group on treatment remained unchanged; while both the
normal caloric groups had a decrease (17.7 % for diet
change only and 25.68 % for diet change with treat-
ment). The difference for the high caloric groups was
non-significant, for the ND change alone the difference
tended towards significance (p = 0.07) while the change
for the animals switched to the HCD with treatment was
significant (p = 0.018).
The result of the serum chemistry parameters is pre-
sented in Table 3. All the values were within the normal
range with the exception of creatinine, urea, alkaline
phosphatase activity (ALP) and alanine aminotransferase
(ALT). The creatinine and urea values for all the mice
are higher than the normal reference values. The normal
reference value is 0.63 ± 0.08 mmol/l for creatinine and
0.9 – 1.2 mmol/l for urea. In addition the ALP value for
mice on HCD are higher than the normal reference
range and significantly higher (p˂0.05) than for the other
animals (128.7 ± 30.51 U/l) while the high ALT value for
mice on HCD with treatment (150.2 ± 122.62 U/l) are
within the normal reference interval for the CD1 mice.
The liver, kidneys, pancreas, heart and blood vessel to
the legs were collected for histological examination. No
pathological changes were observed in the kidneys, heart
and blood vessel to the legs. The most consistent mor-
phological changes in the animals were the hypertrophic
changes in the endocrine islet cells of Langerhans within
the pancreas and metabolic-induce vacuolation and
swelling of the hepatocytes in the liver (hepatosis). Ex-
cessive fat depots were also observed in several of the
animals and excessive fat is one of the predisposing
factors for diabetes. These morphological changes were
induced by the high caloric diet. There was no demarca-
tion apparent between the pathological changes in mice
and the diet consumed.
Discussion
Our results revealed that the in vitro hypoglycaemic ac-
tivities of F. lutea extract were in the ethyl acetate and
n-butanol fractions (intermediate polarity) with the
ethyl acetate fraction having a superior antidiabetic ac-
tivity. The ethyl acetate fraction containing many dif-
ferent compounds at a concentration of 250 μg/ml had
a similar level of activity as the positive control glibencla-
mide, a pure compound at a concentration of c. 50 μg/ml.
This may indicate that the ethyl acetate fractions could
contain compounds as effective as or better than
glibenclamide.
The ethyl acetate fraction was a polyphenol-rich extract
containing compounds including epiafzelechin [9], and cat-
echins and epicatechins (unpublished data), that potently
inhibited α-glucosidase activity and influenced glucose up-
take of C2C12 muscle cells and H-4-II-E liver cells as well
as enhanced insulin release of RIN-m5F pancreatic cell. In
some Ficus species the polyphenol rich extracts were identi-
fied in the intermediate polar fractions either in the ethyl
acetate fraction or the butanol fraction [17, 18], supporting
our findings. Polyphenol-rich extracts are known to in-
fluence carbohydrate metabolism and glucose homeo-
stasis through various mechanisms of which the most
common are delaying of glucose absorption through in-
hibition of the activities of α-amylase and α-glucosidase
thereby blunting post-prandial hyperglycaemia, stimu-
lating of insulin release and increasing the numbers of
glucose transporters [9, 19, 20].
Based on its superior in vitro antidiabetic activity, the
ethyl acetate fraction was investigated further for in vivo
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activity. In this study obesity and its concomitant pre-
diabetic condition, characterised by mild pancreatic
changes and associated changes in GTT were induced in
normal male CD1 mice placed on HCD ad libitum for a
total period of 13 weeks. Hereafter they were placed in
one of the four treatment plans. Treatment plan 1 was
to simulate the practice of failing to reduce caloric in-
take in a weight loss programme while treatment plan 2
was essentially to simulate the standard practice of de-
creasing caloric intake in a weight loss programme.
One of the problems with induction diabetic studies is
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Fig. 5 The effect of diets on blood glucose concentrations of CD1 mice. a Fasting blood glucose and GTT at period 0 when obese state was
attained by mice prior to commencement of treatment, (b) Fasting blood glucose and GTT of mice after 6 weeks of treatment and (c) Area
under the curve (AUC) of glucose concentration. AUC was calculated from curves of blood glucose levels (mM) verses time intervals (min). AUC
before treatment was glucose response at period 0 when obese state was induced in mice. AUC after treatment was glucose response at period
21 after treatment (Rx). Values are the mean ± SEM. **Statistical difference between AUC before and AUC after treatment (p˂0.01)
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evaluation of the efficacy results. For this study we be-
lieve that the animals were pre-diabetic for the following
reasons. The mice on the high caloric induction diet
showed an increase in body mass and obesity, with ele-
vated blood glucose concentrations. The trend towards
diabetic nephropathy which develops as a result of
chronic hyperglycaemia was also present in the study an-
imals as seen with the increase in plasma creatinine and
urea concentrations [21, 22]. The histopathology report
also indicated that the animals were pre-diabetic as the
animals had moderate to excessive fat deposit in the ab-
dominal cavity, mild to moderate cell swelling with vacu-
olated changes within the cytoplasm of the hepatocytes
with accumulation of fatty acids suggesting metabolic-
induced fatty acid changes of the liver and enlargement
of the pancreatic islets of β-cell [23, 24].
With insulin resistance being fundamental in the
pathogenesis of type II diabetes, intervention is initially
aimed towards improvement in tissue sensitivity/respon-
siveness with modulation of weight being suggested as a
better treatment modality. Weight loss is known to im-
prove insulin sensitivity and overall glycaemic control,
and to decrease mortality rates [25]. While a change in
diet alone can result in moderate weight loss, this is dif-
ficult to achieve in the long term as weight lost is slowly
regained due to the physiological abnormalities induced
by obesity [25]. As a result it has been suggested that
weight loss may be enhanced through combination with
pharmacological agents that can reduce or control
weight by altering appetite, metabolism, decreased fat
absorption or consumption of calories [26, 27]. Of these,
much emphasis has been place on the inhibition of the
glucosidase and amylase enzymes. Inhibition of these en-
zymes, particularly of α-glucosidase in the small intes-
tine, which catabolises non-absorbable complex
carbohydrates into absorbable monosaccharides will
modulate blood glucose concentration and weight gain
[28]. The α-glucosidase and α-amylase enzyme inhibitors
regulate blood glucose, especially postprandial blood
glucose by limiting the rate of starch and sucrose metab-
olism, delaying the absorption of glucose and fructose in
the gastrointestinal tract and the gastric emptying rate,
which further alters the secretion of insulin [28]. In
addition, the limiting the rate of starch metabolism may
promote weight loss by reducing the digestive availability
of carbohydrate derived calories [29].
The search for newer weight controlling agents from
plant polyphenols may be an alternate source or adjunct
means of controlling diabetes [30]. For this reason the
obese mice were exposed to the ethyl acetate fraction of
F. lutea, in an attempt to establish the effect of the ex-
tract in the pre-diabetic condition in the presence or ab-
sence of dietary modification. Since the animals were
allowed ad lib. access to food, the test extract was in-
cluded within the food. The reason for this was that
acarbose, a known α-glucosidase inhibitor, is recom-
mended for use on consumption of the main meals [31].
For this study, the mice placed on treatment without a
change in their caloric intake maintained a steady weight
throughout the study in comparison to further increases
in the control animals which received the HCD alone.
This suggests that in cases of high caloric intake, the
ethyl acetate fraction of F. lutea could potentially miti-
gate further weight gain. When the mice were switched
from high caloric to a normo-caloric intake, it did not
lead to statistically significant gain or loss of weight, in
the presence or absence of the F. lutea ethyl acetate frac-
tion. This indicates that the extract fraction in itself was
not a weight loss agent. The failure of the mice to lose
weight when switched from the high caloric to the
normo-caloric diet was also not unexpected as other au-
thors found that switching to a low caloric diet is
Table 3 The effect of diets (with or without ethyl acetate fraction) on serum chemistry parameters of CD1 mice
Serum chemistry
parameters
Treated Group aUntreated group
High Caloric High Caloric with Treatment Normal diet Normal diet with Treatment Standard rodent diet
Total protein (g/l) 51.3 ± 1.52 52.1 ± 0.90 52.2 ± 0.92 50.1 ± 0.94 46 – 58
Albumin (g/l) 25.2 ± 1.85 23.6 ± 1.56 24.6 ± 1.97 23.4 ± 1.06 24 – 32
Globulin (g/l) 26.2 ± 1.25 28.7 ± 1.00 27.9 ± 1.55 26.7 ± 1.02 20 – 28
Albumin/globulin ratio 1.0 ± 0.0 0.9 ± 0.11 0.9 ± 0.10 1.0 ± 0.0 0.96 – 1.36
ALT (U/l) 21.2 ± 1.33 150.2 ± 122.62* 79.0 ± 30.50 76.6 ± 28.10 66 – 170
ALP (U/l) 128.7 ± 30.51* 57.7 ± 14.44 54.5 ± 4.83 52.3 ± 3.57 72 – 118
Cholesterol (mmol/l) 4.7 ± 0.56 4.8 ± 0.36 3.9 ± 0.23 3.7 ± 0.24 3.7 – 5.7
Urea (mmol/l) 4.5 ± 0.34 4.1 ± 0.42 9.3 ± 0.50 8.4 ± 0.36 0.9 – 1.2
Creatinine (mmol/l) 9.0 ± 0.0 10.1 ± 1.11 9.0 ± 0.0 8.7 ± 0.27 0.63 ± 0.08
Triglycerides (mmol/l) 1.3 ± 0.33 1.0 ± 0.17 1.3 ± 0.21 1.7 ± 0.20 10.7 ± 0.08
*Statistical difference between treatment and control groups (p˂0.05)
aRiver [38]
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required for a substantial weight loss [30, 32]. This
was similar to findings of Veerapur et al. [33], who ob-
served that Ficus racemosa extract did not affect body
weight and food intake in high fat diet (HFD) fed Al-
bino Wistar male rats. Also supplementation of feed
with cyanidin 3-glucoside did not affect the body
weight in either HFD and db/db male mice or signifi-
cantly change food intake during the experimental
period [34]. Hou et al. [35] found no significance body
weight change between the group receiving a normal
standard diet and high carbohydrate – high fat diet
(HC-HF) as well as between the groups of the HC-HF
diet and metformin administration.
Further evidence supporting the inability of the ethyl
acetate fraction of F. lutea to stimulate weight loss can be
seen with the failure of the extract to induce a change in
either faecal weight or the extent of nutrient absorption in
the mice per treatment group in comparison to their con-
trol group. This differed from other studies, where the fae-
cal weights of animals fed polyphenol-rich diet were
significantly higher than those on a control diet [36, 37].
These authors speculated that polyphenols adsorb choles-
terol, bile acids and dietary lipid thereby increasing faecal
excretion. The reason for the failure of the ethyl acetate
fraction to induce similar changes is unclear, but it could
be speculated that in contrast to other studies, the ethyl
acetate fraction of F. lutea does not inhibit the activity of
pancreatic lipase, a key enzyme in the digestion and ab-
sorption of fat [36, 37].
An important result of this study was the decrease in
the AUC of the glucose concentration versus time profiles
in those animals that were treated with both a change in
diet and the plant extract. With all the treatment groups
showing the same time to peak in blood glucose concen-
trations (Tmax), conventional pharmacological principles
indicate that the induced changes were not due to a
change in the rate of glucose absorption, but rather to a
change in the total extent of absorption or an increased
depletion rate of plasma concentrations subsequent to ab-
sorption. Based on the in vitro effect of the plant extract,
both these effects are possible. However considering that
the plant extract failed to induce a change in faecal
weights, the more likely mechanism is an increase in the
depletion of glucose within the plasma. Since the latter is
linked to increased uptake within the cells, the most likely
mechanism is either an increased insulin response or
increased insulin secretion. From the in vitro work, we
believe that the effect is due to the stimulation of insu-
lin secretion and perhaps not inhibition of activities of
the α-amylase and α-glucosidase.
Conclusion
The polyphenol-rich ethyl acetate fraction of F. lutea ex-
tract was the most active fraction. In in vitro assays,
ethyl acetate fraction, an intermediate polarity solvent,
potently inhibited α-glucosidase activity, enhanced su-
perior glucose uptake of muscle and liver cells, and
stimulated insulin secretion. For the in vivo assays, al-
though the ethyl acetate fraction of F. lutea extract
exerted no statistical significant weight loss benefit in
the treatment groups compared to their control, it sig-
nificantly attenuated AUC profiles in the animals that
were treated with both a change in diet and the plant
extract. Future work will be to investigate the changes
in plasma insulin concentrations following treatment
with the ethyl acetate fraction of crude F. lutea acetone
polyphenol extracts to determine the mechanisms of
ameliorating hyperglycaemia.
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